国家医学研究中心 National Center for Medical Research
医学研究分类：1. 根据是否存在人为干预措施分为观察性研究（Observational Study）和实验性研究（Experimental Study）；2. 观察性研究根据有无对照组分为描述性研究（Descriptive Study）和分析性研究（Analytical Study）; 3. 实验性研究根据是否采用随机采样的方式分为非随机对照组（Non-randomized Controlled Study）和随机对照组(Randomized Controlled Study).
循证医学 evidence-based medicine
前瞻性研究 prospective study
image.png
The National Center for Medical Research (hereinafter referred to as NCMR) is the first national think tank dedicated to health policy research in China. NCMR is a government agency under the Beijing Municipal Health Commission. Our mission is to advance evidence based medicine and industry-academia-research collaboration through proactive patient-oriented and policy-driven research. NCMR has made fruitful results and distinguished itself in the medical research sector by emphasizing game changing discoveries in disease prevention, early diagnosis, and treatment.
国家医学研究中心（National Center for Medical Research，下文简称“NCMR”）是国内首个致力于卫生政策研究的国家级智库单位。本中心是北京市卫生健康委员会直属事业单位，以促进循证医学、助力“产学研”合作为宗旨，积极开展以患者为导向的前瞻性、政策性研究。NCMR重点关注疾病预防及早诊早治方面的突破性研究，医学研究成果突出，在该领域中具有不可替代的地位。
临床研究的题目往往很长，有几个规律：
1）临床试验的修饰词用顿号“、”隔开；
2）疗效对比，行文规则：A “对比”B的疗效
3）单一药物疗效研究，行文规则：XX 治疗XX（不用加“患者”二字）：
A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers (DOC-GC study)
一项双臂、随机、开放标签、前瞻性设计、优效性III期DOC-GC临床试验：多西他赛-奥沙利铂-卡培他滨/5-氟尿嘧啶（DOC/F）序贯多西他赛对比奥沙利铂/奥沙利铂+亚叶酸钙+氟尿嘧啶(mFOLFOX-7)的疗效
A randomized controlled phase III trial comparing thoracoscopic esophagectomy and open esophagectomy for thoracic esophageal cancer: JCOG1409
JCOG1409随机对照III期临床试验：胸腔镜食管切除术对比开放性食管切除术治疗胸段食管癌的疗效
A randomized, multicenter, double-blind, positive controlled, phase II study of Spirulina peptidoglycan complex (K-001) in untreated advanced hepatocellular carcinoma
螺旋藻肽聚糖复合物胶囊对比肝复乐胶囊一线治疗晚期肝细胞癌的随机、多中心、双盲、阳性对照的II期临床试验
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study
一线帕博利珠单抗联合化疗治疗晚期食管癌：III期临床研究中5年生存结局数据（KEYNOTE-590 study）
